Heineman H S, Israel W
Int J Clin Pharmacol Biopharm. 1975 Jul;12(1-2):202-9.
During the first nine months following its release for general use, carbenicillin was administered to forty-two patients in Hahnemann Hospital. Thirty-nine available records of patients receiving the drug for other than urinary infection were reviewed. Among children, all but one had mucoviscidosis: most were given acceptable therapeutic regimens; survival rate was 80%, and their physicians were favorably impressed. Among adults, underlying disease was usually life threatening; most were inadequately treated; survival rate was 31%, and their physicians were not favorably impressed. The multiplicity of variables precludes objective evaluation of the drug under the circumstances of its use, but one that could have been avoided was the inconsistency of the therapeutic regimen, which in adult patients was too often insufficient. As used, therefore, carbenicillin has not provided the benefits predicted from its earlier controlled evaluation, and the large expenditure of money, particularly by adult patients, has been largely wasted.
羧苄青霉素在上市供一般使用后的最初九个月期间,哈内曼医院有42名患者使用了该药。对39份非尿路感染患者使用该药物的现有记录进行了审查。在儿童中,除1名外均患有黏液黏稠症:大多数接受了可接受的治疗方案;存活率为80%,他们的医生对此印象良好。在成人中,基础疾病通常危及生命;大多数治疗不充分;存活率为31%,他们的医生对此印象不佳。变量的多样性使得在药物使用情况下无法对其进行客观评估,但一个本可避免的问题是治疗方案不一致,在成年患者中这种情况经常出现且治疗不足。因此,按照目前的使用情况,羧苄青霉素并未带来早期对照评估所预测的益处,大量的资金支出,尤其是成年患者的支出,很大程度上被浪费了。